Showing 1 - 10 of 24,030
Purpose – The purpose of this paper is to examine the rationale and synergies of a Japanese firm's acquisition of India's leading pharmaceutical firm, Ranbaxy, and to answer the following pertinent questions: could Ranbaxy have been able to survive and succeed, had the firm not gone for this...
Persistent link: https://www.econbiz.de/10013058385
Persistent link: https://www.econbiz.de/10012422946
Pharmaceutical firms spend billions of dollars to develop the next breakthrough drug and to maintain their market shares. We investigate how pharmaceutical firms use mergers and acquisitions to boost their innovation performance which has been found to result in better performance outcomes....
Persistent link: https://www.econbiz.de/10012502063
Persistent link: https://www.econbiz.de/10011616182
Aktuelle Zahlen aus der pharmazeutischen Industrie zeigen, dass die Entwicklung von neuen Produkten immer länger dauert und immer mehr kostet. Zudem schaffen immer weniger Produkte die Hürde der klinischen Entwicklung. Man spricht schon fast von einem Produktivitätsproblem der Forschung und...
Persistent link: https://www.econbiz.de/10010256239
Purpose: In this paper, a practical framework is presented for the successful integration of buyers and contract organizations based on the Critical Incident Technique (CIT). Methodology: The initial pool of situations was developed inductively according to qualitative data provided by ten...
Persistent link: https://www.econbiz.de/10012421505
Persistent link: https://www.econbiz.de/10014252542
Appraising pharmaceutical products at different time points of their lifecycle open ups the possibility of reversals in estimates of economic value. A product that erstwhile was rated “not cost-effective” could later on become 'cost-effective'. This paper investigates, within a single...
Persistent link: https://www.econbiz.de/10013295250